

# Stefan Sleijfer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608429/publications.pdf>

Version: 2024-02-01

160  
papers

5,227  
citations

109321

35  
h-index

106344

65  
g-index

163  
all docs

163  
docs citations

163  
times ranked

9088  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancerâ€™Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). <i>Journal of Clinical Oncology</i> , 2009, 27, 3126-3132.	1.6	611
2	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	21.4	250
3	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. <i>European Journal of Cancer</i> , 2010, 46, 72-83.	2.8	224
4	mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3600-3618.	7.0	207
5	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 455-468.	2.5	171
6	The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. <i>Oncologist</i> , 2016, 21, 1396-1409.	3.7	147
7	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	12.8	130
8	Application of circulating tumor DNA in prospective clinical oncology trials â€™ standardization of preanalytical conditions. <i>Molecular Oncology</i> , 2017, 11, 295-304.	4.6	123
9	PD-L1, Galectin-9 and CD8<sup>+</sup> tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. <i>Onc Immunology</i> , 2017, 6, e1273309.	4.6	117
10	<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1766-1773.	7.0	117
11	Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cellsâ€™a completed study overview. <i>Biochemical Society Transactions</i> , 2016, 44, 951-959.	3.4	115
12	Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. <i>Breast</i> , 2017, 31, 9-15.	2.2	109
13	Circulating tumour cell detection on its way to routine diagnostic implementation?. <i>European Journal of Cancer</i> , 2007, 43, 2645-2650.	2.8	101
14	The potential of statins as part of anti-cancer treatment. <i>European Journal of Cancer</i> , 2005, 41, 516-522.	2.8	92
15	Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib. <i>Hypertension</i> , 2014, 64, 1282-1289.	2.7	78
16	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 52, 33-40.	7.7	75
17	Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 92-92.	1.6	69
18	Correlation between nivolumab exposure and treatment outcomes in nonâ€™small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	2.8	58

#	ARTICLE	IF	CITATIONS
19	The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. <i>Nature Communications</i> , 2021, 12, 4612.	12.8	55
20	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 19283-19293.	1.8	54
21	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. <i>International Journal of Cancer</i> , 2017, 141, 572-582.	5.1	53
22	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	4.6	52
23	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
24	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	6.4	49
25	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014, 4, 7.	2.3	47
26	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2015, 41, 187-196.	7.7	47
27	Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. <i>European Journal of Cancer</i> , 2021, 150, 179-189.	2.8	47
28	Prognostic value of intra-tumoral CD8 <sup>+</sup> /FoxP3 <sup>+</sup> lymphocyte ratio in patients with resected colorectal cancer liver metastasis. <i>Journal of Surgical Oncology</i> , 2018, 118, 68-76.	1.7	46
29	Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. <i>Neoplasia</i> , 2016, 18, 647-653.	5.3	44
30	CD45RA <sup>+</sup> CCR7 <sup>+</sup> CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
31	Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. <i>Cancer Letters</i> , 2015, 362, 36-44.	7.2	41
32	Thalidomide in solid tumours: the resurrection of an old drug. <i>European Journal of Cancer</i> , 2004, 40, 2377-2382.	2.8	40
33	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. <i>Endocrine-Related Cancer</i> , 2014, 21, 653-661.	3.1	39
34	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
35	Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. <i>Nature Communications</i> , 2021, 12, 574.	12.8	39
36	Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib. <i>Hypertension</i> , 2015, 66, 543-549.	2.7	38

#	ARTICLE	IF	CITATIONS
37	mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. <i>Molecular Oncology</i> , 2015, 9, 920-932.	4.6	37
38	Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 95-105.	2.5	37
39	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , 2019, 9, 10677.	3.3	37
40	High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. <i>Molecular Oncology</i> , 2019, 13, 392-402.	4.6	37
41	Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59058-59069.	1.8	37
42	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. <i>Clinical Cancer Research</i> , 2018, 24, 2678-2687.	7.0	35
43	Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. <i>Urology</i> , 2016, 95, 121-127.	1.0	34
44	Mitochondrial DNA content in breast cancer: Impact on <i>in vitro</i> and <i>in vivo</i> phenotype and patient prognosis. <i>Oncotarget</i> , 2016, 7, 29166-29176.	1.8	33
45	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-ESTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32
46	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-confirmed <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32
47	Lysosomal Sequestration Determines Intracellular Imatinib Levels. <i>Molecular Pharmacology</i> , 2015, 88, 477-487.	2.3	30
48	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. <i>Oncotarget</i> , 2016, 7, 43412-43418.	1.8	30
49	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271.		29
50	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. <i>Molecular Oncology</i> , 2021, 15, 57-66.	4.6	28
51	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	3.7	27
52	Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1083-1089.	5.1	27
53	T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients. <i>Frontiers in Immunology</i> , 2016, 7, 648.	4.8	26
54	Whole exome sequencing of cell-free DNA – A systematic review and Bayesian individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 83, 101951.	7.7	26

#	ARTICLE	IF	CITATIONS
55	An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 123.	2.6	25
56	The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 42-50.	7.7	24
57	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 501.	7.1	23
58	AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. <i>Molecular Oncology</i> , 2019, 13, 1795-1807.	4.6	23
59	Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. <i>Oncologist</i> , 2008, 13, 1193-1200.	3.7	22
60	Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered. <i>European Journal of Human Genetics</i> , 2016, 24, 1496-1500.	2.8	22
61	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017, 75, 33-40.	2.8	22
62	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.7	22
63	Circulating tumor cells and survival in abiraterone and enzalutamide-treated patients with castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 435-445.	2.3	21
64	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	3.7	21
65	Active surveillance in desmoid-type fibromatosis: A systematic literature review. <i>European Journal of Cancer</i> , 2020, 137, 18-29.	2.8	21
66	Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. <i>British Journal of Cancer</i> , 2020, 122, 953-956.	6.4	21
67	Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 276-276.	1.6	21
68	The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. <i>European Journal of Cancer</i> , 2014, 50, 972-980.	2.8	20
69	MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 2541-2552.	0.8	20
70	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 48-54.	2.8	20
71	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 651-658.	3.5	20
72	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 204-214.	5.4	20

#	ARTICLE	IF	CITATIONS
73	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).. Journal of Clinical Oncology, 2012, 30, 2593-2593.	1.6	20
74	First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. Oncologist, 2017, 22, 901-909.	3.7	18
75	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers, 2018, 10, 134.	3.7	18
76	Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer, 2021, 21, 315.	2.6	18
77	Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy, 2015, 7, 513-533.	2.0	17
78	Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. Quality of Life Research, 2018, 27, 3097-3111.	3.1	17
79	Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 416-425.	2.8	16
80	Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. European Journal of Cancer, 2016, 56, 101-106.	2.8	16
81	An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. Journal of Molecular Diagnostics, 2018, 20, 316-325.	2.8	15
82	The role of mitochondrial DNA in breast tumors. Drug Discovery Today, 2019, 24, 1202-1208.	6.4	15
83	Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. Clinical Cancer Research, 2017, 23, 4735-4743.	7.0	14
84	Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. Breast Cancer Research and Treatment, 2019, 175, 451-458.	2.5	14
85	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2 <sup>+</sup> postmenopausal breast cancer patients treated with everolimus and exemestane. Molecular Oncology, 2020, 14, 490-503.	4.6	14
86	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. Clinical Cancer Research, 2021, 27, 2798-2806.	7.0	14
87	Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach. Journal of Digital Imaging, 2022, 35, 127-136.	2.9	14
88	Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation. Haematologica, 2015, 100, e246-e249.	3.5	13
89	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. European Journal of Cancer, 2017, 86, 226-232.	2.8	13
90	Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer. ESMO Open, 2020, 5, e000619.	4.5	13

#	ARTICLE	IF	CITATIONS
91	First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 169, 135-145.	2.8	13
92	Current clinical trials for advanced osteosarcoma and soft tissue sarcoma. <i>Current Opinion in Oncology</i> , 2014, 26, 434-439.	2.4	12
93	Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. <i>PLoS ONE</i> , 2017, 12, e0183155.	2.5	12
94	Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review. <i>Cancer Treatment Reviews</i> , 2022, 106, 102384.	7.7	12
95	Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure. <i>Clinical Pharmacokinetics</i> , 2017, 56, 305-310.	3.5	11
96	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	1.8	11
97	Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. <i>Acta Oncologica</i> , 2019, 58, 872-879.	1.8	11
98	Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. <i>European Journal of Radiology</i> , 2020, 131, 109266.	2.6	11
99	Plasma IFN- $\gamma$ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells. <i>Clinical Immunology</i> , 2016, 169, 107-113.	3.2	10
100	Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 477.	4.1	10
101	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. <i>Drug Discovery Today</i> , 2019, 24, 1715-1719.	6.4	10
102	Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. <i>Surgical Oncology</i> , 2019, 29, 84-89.	1.6	10
103	Novel methods to diagnose leptomeningeal metastases in breast cancer. <i>Neuro-Oncology</i> , 2019, 21, 428-439.	1.2	10
104	High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments. <i>Clinical Epigenetics</i> , 2021, 13, 196.	4.1	10
105	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019, 19, 473-479.	2.0	9
106	Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019, 11, 882.	3.7	9
107	The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study) – A Protocol for an International Cohort Study. <i>Cancers</i> , 2021, 13, 3068.	3.7	9
108	Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area. <i>Oncologist</i> , 2015, 20, 241-242.	3.7	8

#	ARTICLE	IF	CITATIONS
109	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. <i>Clinical Sarcoma Research</i> , 2017, 7, 2.	2.3	8
110	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. <i>Scientific Reports</i> , 2020, 10, 2927.	3.3	8
111	Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis. <i>Cancers</i> , 2022, 14, 709.	3.7	8
112	The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. <i>BMC Cancer</i> , 2022, 22, 165.	2.6	8
113	Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. <i>Scientific Reports</i> , 2017, 7, 2136.	3.3	7
114	EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. <i>European Journal of Cancer</i> , 2018, 88, 87-91.	2.8	7
115	Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. <i>Cancers</i> , 2018, 10, 500.	3.7	7
116	Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565031.	2.8	7
117	Assessing the Desmoid-Type Fibromatosis Patients'™ Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. <i>Sarcoma</i> , 2020, 2020, 1-9.	1.3	7
118	In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1527-1535.	1.0	7
119	Clinical value of circulating tumor cells in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 696-698.	27.6	6
120	Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study. <i>Oncologist</i> , 2019, 24, e526-e535.	3.7	6
121	A pipeline for copy number profiling of single circulating tumour cells to assess inpatient tumour heterogeneity. <i>Molecular Oncology</i> , 2022, 16, 2981-3000.	4.6	6
122	Are Immune Signatures a Worthwhile Tool for Decision Making in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 673-675.	1.6	5
123	Affordability of drugs used in oncology health care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 331-332.	27.6	5
124	Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 511-519.	4.4	5
125	Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6975.	4.1	5
126	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. <i>Cells</i> , 2020, 9, 124.	4.1	5



#	ARTICLE	IF	CITATIONS
127	Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 2596-2596.	1.6	5
128	A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.. Journal of Clinical Oncology, 2013, 31, 2522-2522.	1.6	5
129	Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression. JCO Precision Oncology, 2022, 6, e2100190.	3.0	5
130	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating $\beta$ -catenin mutations. European Journal of Surgical Oncology, 2019, 45, 691-698.	1.0	4
131	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. Journal of Personalized Medicine, 2021, 11, 257.	2.5	4
132	ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 5631.	4.1	4
133	Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalsecience, 2018, 12, 825.	1.1	3
134	MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma. PLoS ONE, 2020, 15, e0228014.	2.5	3
135	How to Decide Whether to Offer and Use "Nonstandard" Therapies in Patients with Advanced Sarcomas and Gastrointestinal Stromal Tumors: Global Variations in Clinical Practice, Assessment, and Access to Therapies in Diseases with Limited Incidence and Data. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, ., 645-650.	3.8	3
136	Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 70-71.	4.3	2
137	Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. Journal of Clinical Pharmacology, 2015, 55, 920-925.	2.0	2
138	Letter to the editor: Comments on "A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation"™. European Journal of Cancer, 2020, 138, 54-56.	2.8	2
139	Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 4523-4523.	1.6	2
140	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. Journal of Clinical Oncology, 2013, 31, 10573-10573.	1.6	2
141	Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2014, 32, 10579-10579.	1.6	2
142	CD276-positive circulating endothelial cells in advanced colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 572-572.	1.6	2
143	Prognostic Value of Circulating Tumor Cell Characteristics May Be Biased by Their Quantity. Journal of Clinical Oncology, 2022, 40, 519-520.	1.6	2
144	Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer, 0, ., .	6.4	2

#	ARTICLE	IF	CITATIONS
145	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. <i>Sarcoma</i> , 2019, 2019, 1-11.	1.3	1
146	Adjuvant treatment in patients with melanoma: The planning of scanning. <i>European Journal of Cancer</i> , 2021, 157, 306-307.	2.8	1
147	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOC) side study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22106-e22106.	1.6	1
148	Correlation between nivolumab exposure and treatment outcome in NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9057-9057.	1.6	1
149	Abstract P2-01-17: Circulating tumor cell count and levels of circulating tumor DNA are complementary prognostic biomarkers in metastatic breast cancer - A pilot study. <i>Cancer Research</i> , 2022, 82, P2-01-17-P2-01-17.	0.9	1
150	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
151	EXTH-03. LOCAL ONCOLYTIC ADENOVIRUS TREATMENT AFFECTS BOTH THE INNATE AND ADAPTIVE ARMS OF THE IMMUNE SYSTEM AND PROVIDES AN AVENUE FOR ENHANCING IMMUNOTHERAPIES FOR GBM. <i>Neuro-Oncology</i> , 2018, 20, vi85-vi85.	1.2	0
152	Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity. <i>Clinical Cancer Research</i> , 2020, 26, 3897-3898.	7.0	0
153	Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10553-10553.	1.6	0
154	Phase I study of cisplatin (cDDP)/hyperthermia (HT)/lapatinib (Lap) in patients (pts) with recurrent carcinoma of the uterine cervix (rCC) in previously irradiated area (PIA).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16504-e16504.	1.6	0
155	mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11045-11045.	1.6	0
156	Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11017-11017.	1.6	0
157	Rates of survival throughout the years in soft tissue sarcoma with synchronous metastases: Results of a population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11068-11068.	1.6	0
158	The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5014-5014.	1.6	0
159	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21239-e21239.	1.6	0
160	Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1087-1087.	1.6	0